Savara Inc
$2.23
(as of Jun 27, 3:45 PM EST)
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Ticker Information for Savara Inc
Stock Price
$2.23
Ticker Symbol
SVRA
Exchange
NASDAQ
Industry Information for Savara Inc
Sector
Healthcare
Industry
Biotechnology
Company Description for Savara Inc
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Langhorne, Pennsylvania.
Fundamentals for Savara Inc
Market Capitalization
$586,952,192
EBITDA
$-102,269,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
0
Earnings per Share
$-0.48
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
172,632,992
Percent Owned by Insiders
5.35%
Percent Owned by Institutions
98.04%
52-Week High
52-Week Low
Technical Indicators for Savara Inc
Analyst Ratings for Savara Inc
Strong Buy
4
Buy
3
Hold
1
Sell
0
Strong Sell
0
News About Savara Inc
Jun 23, 2025, 2:42 PM EST
Director Richard J Hawkins (NASDAQ:HWKN) of Savara Inc (NASDAQ:SVRA), a $441 million market cap biotechnology company, acquired 48,225 shares of common stock on June 20, 2025, according to a Form 4 filing with the Securities and Exchange Commission.
See more.
Jun 23, 2025, 12:24 PM EST
NEW YORK, June 23, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. See more.
Jun 18, 2025, 12:06 PM EST
NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Savara Inc. See more.
Jun 14, 2025, 5:25 PM EST
Savara Inc. See more.